Management of Peyronie's disease after collagenase (Xiaflex:®)

Curr Drug Targets. 2015;16(5):484-94. doi: 10.2174/1389450115666141114163128.

Abstract

Although the prevalence of Peyronie's disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting. Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Therapy, Combination / methods*
  • Humans
  • Male
  • Microbial Collagenase / therapeutic use
  • Penile Induration / drug therapy*
  • Penile Induration / epidemiology
  • Penile Induration / rehabilitation*
  • Penile Prosthesis
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Microbial Collagenase